Scientists at Life Biosciences are preparing to begin testing partial reprogramming in people. It will mark the first time ...

A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...

The field of partial reprogramming is transitioning from successful mouse studies to its first human clinical trials. At the heart of this experiment lies the discovery of Yamanaka ...

A single-atom nanozyme mimicking cytochrome c oxidase restores mitochondrial energy production in stem cells, shifting their ...

Ageing reversal may be closer than we think – scientists have begun human trials to test anti-ageing methods.

Life Biosciences, a Boston longevity biotech co-founded by Harvard genetics professor David Sinclair, has locked down an $80 ...

Board of Alders New Haven Notice] The Joint Community Development/Health & Human Services Committee will meet in person on Wednesday, April 15, 2026, at 6:00 P.M, in the Board of Alders Chamber, 165 ...

From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...

Systemic candidiasis is an opportunistic fungal infection that has been difficult to treat effectively. Research published in ...

HexemBio has launched with a seed round led by Draper Associates to advance a blood stem cell rejuvenation therapy backed by Robert Langer.

HexemBio emerges with a breakthrough blood stem cell rejuvenation technology led by Draper Associates and an advisory ...

A first-of-its-kind study led by the Medical University of South Carolina raises questions about the value of fish oil ...